FFA
CRL icon

Fragasso Financial Advisors’s Charles River Laboratories CRL Stock Holding History

Fragasso Financial Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Buy
1,524
+2
+0.1% +$356 0.02% 258
2026
Q1 		$256K Sell
1,522
-450
-23% -$83.4K 0.02% 279
2025
Q4 		$393K Sell
1,972
-664
-25% -$120K 0.02% 214
2025
Q3 		$467K Sell
2,636
-165
-6% -$26.2K 0.03% 200
2025
Q2 		$425K Sell
2,801
-2,140
-43% -$285K 0.03% 199
2025
Q1 		$744K Sell
4,941
-9,597
-66% -$1.61M 0.06% 150
2024
Q4 		$2.68M Sell
14,538
-487
-3% -$93.8K 0.2% 66
2024
Q3 		$2.96M Sell
15,025
-1,440
-9% -$299K 0.23% 66
2024
Q2 		$3.4M Sell
16,465
-9,524
-37% -$2.16M 0.28% 57
2024
Q1 		$7.04M Sell
25,989
-812
-3% -$194K 0.6% 29
2023
Q4 		$6.34M Buy
26,801
+2,836
+12% +$558K 0.58% 26
2023
Q3 		$4.7M Buy
23,965
+265
+1% +$54.4K 0.49% 30
2023
Q2 		$4.98M Buy
23,700
+1,037
+5% +$206K 0.53% 30
2023
Q1 		$4.57M Buy
22,663
+471
+2% +$107K 0.52% 42
2022
Q4 		$4.84M Buy
22,192
+1,287
+6% +$281K 0.56% 43
2022
Q3 		$4.11M Sell
20,905
-274
-1% -$59.1K 0.58% 40
2022
Q2 		$4.53M Buy
21,179
+886
+4% +$216K 0.61% 37
2022
Q1 		$5.76M Sell
20,293
-976
-5% -$301K 0.68% 34
2021
Q4 		$8.01M Sell
21,269
-1,266
-6% -$492K 0.95% 19
2021
Q3 		$9.3M Sell
22,535
-192
-0.8% -$79.7K 1.23% 13
2021
Q2 		$8.41M Sell
22,727
-134
-0.6% -$44.7K 1.13% 15
2021
Q1 		$6.63M Buy
22,861
+268
+1% +$74.5K 0.93% 18
2020
Q4 		$5.64M Sell
22,593
-1,256
-5% -$299K 0.84% 20
2020
Q3 		$5.4M Buy
23,849
+53
+0.2% +$11K 0.9% 19
2020
Q2 		$5.27M Sell
23,796
-2,140
-8% -$342K 0.9% 19
2020
Q1 		$3.27M Buy
25,936
+301
+1% +$45.1K 0.74% 30
2019
Q4 		$3.92M Buy
25,635
+536
+2% +$74.2K 0.66% 34
2019
Q3 		$3.32M Sell
25,099
-108
-0.4% -$14.5K 0.62% 40
2019
Q2 		$3.58M Buy
+25,207
New +$3.42M 0.71% 34

Other funds holding CRL

CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Fragasso Financial Advisors's CRL Position: Q2 2026 in Review

Fragasso Financial Advisors increased its Charles River Laboratories (CRL) stake by 0.13% in Q2 2026, buying an estimated $356 and bringing the position to 1,524 shares worth $346K. The position accounts for 0.02% of the portfolio, ranked #258.

Fragasso Financial Advisors first reported a position in CRL in Q2 2019 and has held it in 29 quarters since. The position peaked at $9.3M in Q3 2021. 193 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Fragasso Financial Advisors held 1,524 shares of Charles River Laboratories worth $346K as of Q2 2026.
  • Fragasso Financial Advisors bought 2 Charles River Laboratories shares in Q2 2026, an estimated $356.
  • Charles River Laboratories made up 0.02% of Fragasso Financial Advisors's portfolio in Q2 2026, its #258 holding.
  • Fragasso Financial Advisors first reported a position in Charles River Laboratories in Q2 2019 and has held it in 29 quarters since.
  • Fragasso Financial Advisors's Charles River Laboratories position peaked at $9.3M in Q3 2021.
  • 193 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Fragasso Financial Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.